MAP2K7 and cancer: Overall, the above studies together have unveiled extraordinary adaptive reprogramming of cancer cells to targeted MEK inhibition at both epigenomic and signalling levels, the former initially triggered the latter, which in turn likely fuelled further epigenomic changes in a positive-feedback manner.